Assessment of eptifibatide clearance by hemodialysis using an in vitro system

Joanna Laizure, Elizabeth B. McNeely, Christie A. Green, Lisa K. Jennings

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/Aims: Eptifibatide is a parenteral glycoprotein IIb-IIIa inhibitor that prevents platelet aggregation. Although contraindicated in dialysis patients due to limited safety and dialysis data, eptifibatide is prescribed in this population and is associated with bleeding complications. This study was done to determine dialysis clearance (CL D ) of eptifibatide using an in vitro system. Methods:Three common dialyzers were tested. In vitro dialysis was performed at a dialysate flow rate of 500 ml/min, 'blood' flow rate (Q B ) of 200 and 400 ml/min, and the minimal ultrafiltration rate. Eptifibatide CL D and fraction removed were calculated for each condition. Results: CL D ranged from 122 to 225 ml/min and was not significantly different among the dialyzers tested. CL D was flow dependent with higher clearances observed at higher Q B . The estimated fraction of eptifibatide removed was 73-83%. Conclusions: These data suggest that hemodialysis is an effective method to decrease the effects of eptifibatide in patients with impaired kidney function.

Original languageEnglish (US)
Pages (from-to)266-271
Number of pages6
JournalBlood Purification
Volume30
Issue number4
DOIs
StatePublished - Dec 1 2010

Fingerprint

Renal Dialysis
Dialysis
Platelet Glycoprotein GPIIb-IIIa Complex
Platelet Aggregation Inhibitors
Dialysis Solutions
Ultrafiltration
In Vitro Techniques
eptifibatide
Hemorrhage
Kidney
Safety
Population

All Science Journal Classification (ASJC) codes

  • Hematology
  • Nephrology

Cite this

Assessment of eptifibatide clearance by hemodialysis using an in vitro system. / Laizure, Joanna; McNeely, Elizabeth B.; Green, Christie A.; Jennings, Lisa K.

In: Blood Purification, Vol. 30, No. 4, 01.12.2010, p. 266-271.

Research output: Contribution to journalArticle

Laizure, Joanna ; McNeely, Elizabeth B. ; Green, Christie A. ; Jennings, Lisa K. / Assessment of eptifibatide clearance by hemodialysis using an in vitro system. In: Blood Purification. 2010 ; Vol. 30, No. 4. pp. 266-271.
@article{b753db0fd82746a49e69ba3b25bfb528,
title = "Assessment of eptifibatide clearance by hemodialysis using an in vitro system",
abstract = "Background/Aims: Eptifibatide is a parenteral glycoprotein IIb-IIIa inhibitor that prevents platelet aggregation. Although contraindicated in dialysis patients due to limited safety and dialysis data, eptifibatide is prescribed in this population and is associated with bleeding complications. This study was done to determine dialysis clearance (CL D ) of eptifibatide using an in vitro system. Methods:Three common dialyzers were tested. In vitro dialysis was performed at a dialysate flow rate of 500 ml/min, 'blood' flow rate (Q B ) of 200 and 400 ml/min, and the minimal ultrafiltration rate. Eptifibatide CL D and fraction removed were calculated for each condition. Results: CL D ranged from 122 to 225 ml/min and was not significantly different among the dialyzers tested. CL D was flow dependent with higher clearances observed at higher Q B . The estimated fraction of eptifibatide removed was 73-83{\%}. Conclusions: These data suggest that hemodialysis is an effective method to decrease the effects of eptifibatide in patients with impaired kidney function.",
author = "Joanna Laizure and McNeely, {Elizabeth B.} and Green, {Christie A.} and Jennings, {Lisa K.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1159/000320766",
language = "English (US)",
volume = "30",
pages = "266--271",
journal = "Blood Purification",
issn = "0253-5068",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Assessment of eptifibatide clearance by hemodialysis using an in vitro system

AU - Laizure, Joanna

AU - McNeely, Elizabeth B.

AU - Green, Christie A.

AU - Jennings, Lisa K.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background/Aims: Eptifibatide is a parenteral glycoprotein IIb-IIIa inhibitor that prevents platelet aggregation. Although contraindicated in dialysis patients due to limited safety and dialysis data, eptifibatide is prescribed in this population and is associated with bleeding complications. This study was done to determine dialysis clearance (CL D ) of eptifibatide using an in vitro system. Methods:Three common dialyzers were tested. In vitro dialysis was performed at a dialysate flow rate of 500 ml/min, 'blood' flow rate (Q B ) of 200 and 400 ml/min, and the minimal ultrafiltration rate. Eptifibatide CL D and fraction removed were calculated for each condition. Results: CL D ranged from 122 to 225 ml/min and was not significantly different among the dialyzers tested. CL D was flow dependent with higher clearances observed at higher Q B . The estimated fraction of eptifibatide removed was 73-83%. Conclusions: These data suggest that hemodialysis is an effective method to decrease the effects of eptifibatide in patients with impaired kidney function.

AB - Background/Aims: Eptifibatide is a parenteral glycoprotein IIb-IIIa inhibitor that prevents platelet aggregation. Although contraindicated in dialysis patients due to limited safety and dialysis data, eptifibatide is prescribed in this population and is associated with bleeding complications. This study was done to determine dialysis clearance (CL D ) of eptifibatide using an in vitro system. Methods:Three common dialyzers were tested. In vitro dialysis was performed at a dialysate flow rate of 500 ml/min, 'blood' flow rate (Q B ) of 200 and 400 ml/min, and the minimal ultrafiltration rate. Eptifibatide CL D and fraction removed were calculated for each condition. Results: CL D ranged from 122 to 225 ml/min and was not significantly different among the dialyzers tested. CL D was flow dependent with higher clearances observed at higher Q B . The estimated fraction of eptifibatide removed was 73-83%. Conclusions: These data suggest that hemodialysis is an effective method to decrease the effects of eptifibatide in patients with impaired kidney function.

UR - http://www.scopus.com/inward/record.url?scp=78149319897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149319897&partnerID=8YFLogxK

U2 - 10.1159/000320766

DO - 10.1159/000320766

M3 - Article

C2 - 21071937

AN - SCOPUS:78149319897

VL - 30

SP - 266

EP - 271

JO - Blood Purification

JF - Blood Purification

SN - 0253-5068

IS - 4

ER -